New pancreatic cancer drug daraxonrasib shows breakthrough in survival

Key Points:

• Daraxonrasib, a new pancreatic cancer drug targeting KRAS mutations, nearly doubled survival rates in clinical trials, with advanced pancreatic cancer patients living about 15 months compared to the historical average of less than 7 months.
• The FDA granted daraxonrasib Breakthrough Therapy and Orphan Drug designations and approved expanded access in May 2026, with full approval anticipated later in the year pending further results.
• Daraxonrasib works by binding RAS to a chaperone protein, inhibiting KRAS mutations across seven variants, making it the first pan-RAS inhibitor and a potential game-changer in targeted pancreatic cancer therapy.
• Side effects of daraxonrasib are generally manageable, including rashes, diarrhea, and nausea, but it preserves patients' quality of life better than traditional chemotherapy, which often causes hair loss and low blood counts.
• Advances in AI are improving early detection of pancreatic cancer and aiding research into tumor microenvironments and drug resistance, while immunotherapy and surgical innovations also show promise in enhancing treatment outcomes.